The American Thyroid Association (ATA) guidelines suggest to assess TSH in pregnant women at high risk as soon as pregnancy is confirmed and add anti-TPO antibodies to the screening if subclinical hypothyroidism (TSH 2.5–10 mU/L) is found; treatment with L-thyroxine is administered whenever TSH is above 10 mU/L or if subclinical hypothyroidism is associated with positive anti-TPO antibodies [1]. Here, TPO is linked to thyroid gland disorder.